Organon & Co. (NYSE:OGN) Hits New 52-Week High - Should You Buy?

Key Points

• Organon & Co. reached a new 52-week high of $13.77, with shares trading near $13.7650 and a market capitalization of approximately $3.61 billion.
• Analyst sentiment remains cautious: five analysts rate the stock a Hold and two rate it a Sell, resulting in a consensus rating of “Reduce” and a target price of $11.40. Weiss Ratings also lowered its rating from “hold (c)” to “hold (c-).”
• The company declared a quarterly dividend of $0.02 per share, equating to $0.08 annually and a 0.6% yield. Institutional investors own 77.43% of Organon’s shares, with several large investors establishing or expanding positions recently.

Organon & Co. (NYSE:OGN - Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $13.77 and last traded at $13.7650, with a volume of 1003 shares traded. The stock had previously closed at $13.76.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a research report on Monday, August 3rd. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Reduce" and a consensus target price of $11.40.

Organon & Co. Trading Down 0.0%

The firm has a market capitalization of $3.61 billion, a PE ratio of 17.88, a P/E/G ratio of 1.27 and a beta of 1.55. The stock's 50-day simple moving average is $13.58 and its 200-day simple moving average is $11.12. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Organon & Co.'s dividend payout ratio (DPR) is 10.39%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Absolute Gestao de Investimentos Ltda. bought a new position in Organon & Co. in the 2nd quarter valued at approximately $9,007,000. Groupe la Francaise purchased a new stake in Organon & Co. in the second quarter worth approximately $10,499,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Organon & Co. in the second quarter worth approximately $770,000. California State Teachers Retirement System grew its holdings in shares of Organon & Co. by 1,142.8% in the second quarter. California State Teachers Retirement System now owns 4,064,911 shares of the company's stock worth $55,039,000 after acquiring an additional 3,737,836 shares during the period. Finally, Readystate Asset Management LP bought a new stake in shares of Organon & Co. during the 2nd quarter valued at about $4,764,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source